Active Filters

S1404 QoL results
Nov 23, 2022
Patients with high-risk melanoma had better quality of life on pembrolizumab than on standard immunotherapy regimens
SWOG Results at SABCS 2022
Nov 21, 2022
SWOG researchers will present 10 abstracts at SABCS 2022. Here are highlights.
Stratification factors can reduce statistical power
Nov 3, 2022
Adding stratification factors can reduce a small trial’s statistical power
S1801 Melanoma Results at ESMO 2022
Sep 11, 2022
SWOG researchers have found that starting pembrolizumab before surgery instead of waiting until after surgery significantly improves the outlook for patients with stage III-IV melanoma.
S0931 EVEREST results at ASCO 2022
Jun 3, 2022
S0931 found everolimus after surgery tended to increase recurrence-free survival time in patients with high-risk kidney cancer, although results narrowly missed reaching statistical significance
Lung-MAP S1800A results at ASCO 2022
Jun 3, 2022
Ramucirumab plus pembrolizumab combination reduced risk of death by 31 percent compared to standard of care in patients with advanced non-small cell lung cancer that had progressed on prior immunotherapy.
ACA Medicaid Expansion and SWOG Trial Participants
Jun 1, 2022
Affordable Care Act’s expansion of Medicaid in 2014 was followed by a significant rise in proportion of enrollees in group’s cancer trials insured by Medicaid.